Strategic Analysis of the European Diabetes Diagnostics Market

SUMMARY

Increasing Levels of Diabetes Awareness in Europe offer a Growing Market for Diabetes Diagnostic Monitoring Systems

In line with global trends, diabetes has become a multibillion-dollar industry in Europe. Type 2 diabetes alone contributes to an annual economic cost of €29 billion between Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom. Increasing levels of diabetes awareness among patients, physicians and healthcare professionals has given rise to a market for a variety of devices designed to precisely monitor glucose while easing the burden of frequent blood tests. Traditionally, urine testing has been the only method for gauging blood glucose levels in the patient's system. However, owing to its imprecise nature and inability to detect low blood glucose levels, there is a growing demand for portable glucose meters that are compact, user-friendly and efficiently accurate.

This Frost & Sullivan research service covers the European diabetes diagnostics market. The study focuses on market dynamics, current market drivers and provides forecasts for emerging trends. It also looks at the industry challenges and potential threats and makes strategic recommendations for boosting market share.

Point-of-Care Testing is the Largest Profit Making Segment in the Market

Early detection of diabetes is very important in managing the disease. Vast technological improvements in the point-of-care (PoC) technology have made PoC testing an easy approach to the conventional monitoring techniques, since it provides quick and simple results. With the increasing complexity of data and analysis interpretation, PoC testing is expected to play a key role in the fight against diabetes and will dominate the market over clinical diagnostics. The clinical diagnostic segment has seen numerous consolidations of laboratories and industry participants. This has meant that the same numbers of patients are now sampled by fewer laboratories, thus increasing business per customer and allowing laboratories to negotiate better deals from suppliers.

The level of PoC and laboratory testing will vary little over the next several years. However, the use of glycated haemoglobin (HbA1c) testing is expected to rise slightly as general practitioner surgeries, healthcare and outpatient clinics and small hospital-based laboratories more readily adopt this technology. "A large part of HbA1c testing is being transferred to outsourced service providers or reference laboratories, where tests are being processed at prices far cheaper than hospital-based laboratories," notes the analyst.

Anticipating Customer Needs and Improving Diagnostic Technology will Drive Future Growth

The European diabetes diagnostic market has reached a mature stage and this is likely to limit profitability. Manufacturers will have to identify the customers' unmet needs and develop competent technologies that focus on dedicated systems to improve cost efficiency and profitability. Despite increasing the levels of diabetes awareness, at least one-third of the people with diabetes are unaware of their condition. While this highlights a vast market for diagnostic equipment, patients and potential patients need to be educated to encourage the use of testing and monitoring as part of regular physical examinations.

"Though conventional blood testing, which is mainly conducted through PoC products (hand-held, desktop and laboratory) remains the gold standard in glucose monitoring, today's pinprick meters do faster tests, using lesser blood sample quantities than possible before," says the analyst. "However, challenges still remain for more patient-friendly screening and treatments that can gather a wealth of data for diabetes management and information." The future of diabetes care is clustered with non-invasive devices and technologies that make glucose regulation far more accurate and easier to manage.

TABLE OF CONTENTS

• 1. Strategic Analysis of the European Diabetes Diagnostics Market
  • 1. Overview
    • 1. Overview
  • 2. Research Scope and Methodology
    • 1. Research Scope and Methodology
  • 3. Introduction and Background
    • 1. Key Definitions and Abbreviations
    • 2. Exchange Rates
    • 3. Introduction
    • 4. Overview
    • 5. Global Projections I-III
    • 6. Types of Diabetes I-II
    • 7. Diabetes Complications I-II
    • 8. Glucose Testing I-III
    • 9. Economic Impact
  • 4. Market Dynamics
    • 1. Market and Technology Trends I-II
    • 2. Industry Challenges
    • 3. Key Market Drivers
    • 4. Market Drivers
    • 5. Key Market Restraints
    • 6. Market Restraints
    • 7. Market Status and Size
    • 8. Commercial and Emerging Trends
    • 9. Commercial Testing
  • 5. Total Market Forecasts
    • 1. Assumptions
    • 2. Key Market Engineering Measurements
    • 3. EU Diabetes Diagnostics Market Revenue Forecast
    • 4. Segmentation of Diabetes Diagnostic Market
    • 5. Revenue Forecasts by Segments
    • 6. Segmentation Revenue Analysis
    • 7. Company Profiles
  • 6. Strategic Analysis and Recommendations
    • 1. Major Challenges and Strategies
    • 2. Strategic Anticipation
    • 3. Potential Threats
    • 4. Competitive Framework
    • 5. Three Levels of Strategies
    • 6. Pricing Strategy
    • 7. Meeting the Challenge
    • 8. What can be Expected in the Future?
  • 7. Frost & Sullivan Awards
    • 1. Frost & Sullivan Awards
    • 2. Competitive Strategy Leadership Award
    • 3. Product Innovation Award
    • 4. Technology Innovation Award
    • 5. Growth Strategy Leadership Award
    • 6. Marketing Strategy Leadership Award
  • 8. Industry Participants
    • 1. Industry Participants
  • 9. Decision Support Databases
    • 1. Decision Support Databases
  • 10. Frost & Sullivan
    • 1. Healthcare Team
• 2. Our Capabilities